AU2018338098B2 - Cyclic iminopyrimidine derivatives as kinase inhibitors - Google Patents

Cyclic iminopyrimidine derivatives as kinase inhibitors Download PDF

Info

Publication number
AU2018338098B2
AU2018338098B2 AU2018338098A AU2018338098A AU2018338098B2 AU 2018338098 B2 AU2018338098 B2 AU 2018338098B2 AU 2018338098 A AU2018338098 A AU 2018338098A AU 2018338098 A AU2018338098 A AU 2018338098A AU 2018338098 B2 AU2018338098 B2 AU 2018338098B2
Authority
AU
Australia
Prior art keywords
oxy
quinazolin
sulfonamide
propane
dihydroimidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018338098A
Other languages
English (en)
Other versions
AU2018338098A1 (en
Inventor
Chen Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abm Therapeutics Corp
Original Assignee
Abm Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abm Therapeutics Corp filed Critical Abm Therapeutics Corp
Publication of AU2018338098A1 publication Critical patent/AU2018338098A1/en
Application granted granted Critical
Publication of AU2018338098B2 publication Critical patent/AU2018338098B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018338098A 2017-09-20 2018-09-20 Cyclic iminopyrimidine derivatives as kinase inhibitors Active AU2018338098B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561142P 2017-09-20 2017-09-20
US62/561,142 2017-09-20
PCT/US2018/052047 WO2019060611A1 (en) 2017-09-20 2018-09-20 CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES

Publications (2)

Publication Number Publication Date
AU2018338098A1 AU2018338098A1 (en) 2020-05-07
AU2018338098B2 true AU2018338098B2 (en) 2024-02-22

Family

ID=64457074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018338098A Active AU2018338098B2 (en) 2017-09-20 2018-09-20 Cyclic iminopyrimidine derivatives as kinase inhibitors

Country Status (9)

Country Link
US (2) US11254680B2 (https=)
EP (1) EP3684772B1 (https=)
JP (1) JP7394768B2 (https=)
KR (1) KR102796209B1 (https=)
CN (1) CN111247152B (https=)
AU (1) AU2018338098B2 (https=)
CA (1) CA3076202A1 (https=)
MX (1) MX2020003126A (https=)
WO (1) WO2019060611A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
PH12022551118A1 (en) * 2019-12-10 2023-09-18 Hoffmann La Roche New braf inhibitors as paradox breakers
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
CA3179671A1 (en) * 2020-08-07 2022-02-10 Abm Therapeutics Corporation Kinase inhibitors and uses thereof
CN114380697A (zh) * 2021-11-30 2022-04-22 上海毕得医药科技股份有限公司 一种n-甲基乙基胺盐酸盐的制备工艺
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
CN117209503B (zh) * 2023-09-13 2025-10-17 苏州翔实医药发展有限公司 一种5,6-二氢咪唑并[1，2-c]喹唑啉及其衍生物合成的方法
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
TW202545530A (zh) * 2024-01-17 2025-12-01 大陸商海思科醫藥集團股份有限公司 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用
TW202539670A (zh) * 2024-02-23 2025-10-16 大陸商海思科醫藥集團股份有限公司 Braf抑制劑的製備方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82205C2 (en) * 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
US20100216779A1 (en) 2007-06-01 2010-08-26 Glaxosmithkline Llc Imidazopyridine Kinase Inhibitors
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
PL2647637T3 (pl) * 2010-12-02 2016-06-30 Medpacto Inc Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
CN104703599A (zh) * 2012-09-14 2015-06-10 永恒生物科技公司 作为蛋白激酶抑制剂的氨基异喹啉衍生物
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9321762B2 (en) 2013-12-11 2016-04-26 Development Center For Biotechnology Quinazoline compounds, method for preparing the same and use thereof
CN105272970A (zh) 2014-07-03 2016-01-27 中国药科大学 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途
MX385110B (es) * 2014-07-16 2025-03-11 Dev Ct Biotechnology Compuestos de quinoxalina, método para preparar los mismos y uso de los mismos.
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WENGLOWSKY STEVE ET AL: "Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600Ekinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 8, 2014, pages 1923 - 1927 *

Also Published As

Publication number Publication date
JP7394768B2 (ja) 2023-12-08
US11932647B2 (en) 2024-03-19
EP3684772B1 (en) 2023-12-06
RU2020113707A (ru) 2021-10-20
JP2020534373A (ja) 2020-11-26
RU2020113707A3 (https=) 2021-12-23
US20220251089A1 (en) 2022-08-11
CN111247152A (zh) 2020-06-05
EP3684772C0 (en) 2023-12-06
CN111247152B (zh) 2024-07-16
KR20200055034A (ko) 2020-05-20
BR112020005455A2 (pt) 2020-09-24
MX2020003126A (es) 2020-10-01
AU2018338098A1 (en) 2020-05-07
CA3076202A1 (en) 2019-03-28
EP3684772A1 (en) 2020-07-29
WO2019060611A1 (en) 2019-03-28
KR102796209B1 (ko) 2025-04-16
US20200247813A1 (en) 2020-08-06
US11254680B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
AU2018338098B2 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
AU2021326209B2 (en) EFGR inhibitor, preparation method therefor, and application thereof
US11091500B2 (en) Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
US10947246B2 (en) Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
CA2698018C (en) Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
AU2021389180A1 (en) Heteroaryl carboxamide compound
BR112016003247B1 (pt) Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
JP2016513685A (ja) クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法
CA3179671A1 (en) Kinase inhibitors and uses thereof
EP3373931A1 (en) Heterocyclic compounds for the treatment of disease
CN106795152A (zh) 蛋白激酶抑制剂
CA3179325A1 (en) Kinase inhibitors and uses thereof
TW202434590A (zh) 稠合雙環化合物
JP2021518855A (ja) Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ
BR112020005455B1 (pt) Compostos derivados de iminopirimidina cíclica, composição farmacêutica que os compreende, seu uso e método in vitro ou ex vivo para inibir atividade de uma cinase b-raf v600e em uma célula
WO2018220253A1 (es) Derivados de ácidos carboxílicos eficaces como inhibidores de la proteína quinasa
HK40031627A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
HK40031627B (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
CA3225475A1 (en) Heterocyclic compounds and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)